美国肝病患者的经济困难与因费用相关的用药不依从
基于2020-2021年美国国家健康访谈调查的横断面分析显示,肝病/肝硬化患者因经济困难无法支付医疗账单的比例为18.2%,因费用相关用药不依从比例为19.8%,均高于美国成人的6.9%和10.7%;肝病/肝硬化与上述经济困难及用药不依从独立相关,且在65岁以下人群更明显。
要点
- 肝病/肝硬化患者因经济困难无法支付医疗账单的比例为18.2%(95%CI 14.5%-22.6%),高于美国成人的6.9%。
- 肝病/肝硬化患者费用相关用药不依从比例为19.8%(95%CI 15.9%-24.5%),美国成人为10.7%。
- 肝病/肝硬化与因经济困难无法支付医疗账单及费用相关用药不依从独立相关,65岁以下人群差异更明显。
核心结论
- 因医疗账单导致的经济困难和费用相关用药不依从可能对慢性肝病患者产生负面影响,需要进一步评估。
主要发现
- 美国成人中6.9%(95%CI 6.7%-7.2%)报告经济困难且无力支付医疗账单。
- 肝炎、肝病/肝硬化、肝癌患者因经济困难无力支付医疗账单的比例分别为10.6%(95%CI 8.3%-13.4%)、18.2%(95%CI 14.5%-22.6%)、22.6%(95%CI 11.0%-41.0%)。
- 肝病/肝硬化和肝癌患者费用相关用药不依从比例分别为19.8%(95%CI 15.9%-24.5%)和23.3%(95%CI 12.5%-39.3%),美国成人为10.7%(95%CI 10.3%-11.2%)。
- 肝病/肝硬化与因医疗账单导致的经济困难和费用相关用药不依从独立相关,这些差异在65岁以下人群中更明显。
- 超过40%的肝病/肝硬化患者报告在COVID-19大流行期间获取医疗照护困难,肝病/肝硬化与因COVID-19导致获取医疗照护困难独立相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Economic hardship associated with chronic liver disease (CLD) may delay timely access to healthcare. AIM: To estimate the national burden of financial hardship across the spectrum of CLD in the United States (US) during the coronavirus disease 2019 (COVID-19) pandemic. METHODS: A cross-sectional analysis was performed using the 2020-2021 US National Health Interview Survey database. The questionnaire defined financial hardship from medical bills and cost-related nonadherence to medications in patients with CLD. We used weighted survey analysis to obtain the national estimates. RESULTS: While 6.9% (95% confidence interval [CI]: 6.7%-7.2%) out of 60,689 US adults (weighted sample: 251 million) reported financial hardship and inability to pay medical bills; 10.6% (95% CI: 8.3%-13.4%), 18.2% (95% CI: 14.5%-22.6%), 22.6% (95% CI: 11.0%-41.0%) with hepatitis, CLD/cirrhosis, and liver cancer experienced an inability to pay their medical bills due to financial hardship, respectively. 19.8% (95% CI: 15.9%-24.5%) and 23.3% (95% CI: 12.5%-39.3%) with CLD/cirrhosis and liver cancer, respectively experienced cost-related nonadherence to medications, compared to a tenth of US adults (10.7%, 95% CI: 10.3%-11.2%). CLD/cirrhosis demonstrated an independent association with financial hardship from medical bills and cost-related nonadherence to medications. Overall, these disparities were more pronounced in individuals aged <65 years old. In addition, over 40% of individuals with CLD/cirrhosis reported difficulties accessing medical care during the COVID-19 pandemic. CLD/cirrhosis showed an independent association with difficulties accessing medical care due to COVID-19. CONCLUSIONS: Financial hardship from medical bills and cost-related nonadherence to medication can negatively impact individuals with CLD and need further evaluation.
引用
- Kim D, Manikat R, Wijarnpreecha K, et al. Financial hardship and cost-related nonadherence to medication in patients with liver disease in the United States. Aliment Pharmacol Ther. 2024. PMID: 38864288. doi:10.1111/apt.18122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。